Myriam Labopin
#157,487
Most Influential Person Now
Researcher
Myriam Labopin's AcademicInfluence.com Rankings
Myriam Labopincomputer-science Degrees
Computer Science
#8758
World Rank
#9208
Historical Rank
Machine Learning
#3673
World Rank
#3719
Historical Rank
Artificial Intelligence
#3984
World Rank
#4042
Historical Rank
Database
#5759
World Rank
#5975
Historical Rank
Download Badge
Computer Science
Myriam Labopin's Degrees
- PhD Computer Science Université Paris Cité
- Masters Artificial Intelligence Stanford University
- Bachelors Computer Science Université Paris Cité
Similar Degrees You Can Earn
Why Is Myriam Labopin Influential?
(Suggest an Edit or Addition)Myriam Labopin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. (2004) (1108)
- Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) (2005) (428)
- Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. (2007) (416)
- A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. (2013) (342)
- Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases (2010) (322)
- Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. (2017) (307)
- A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. (2008) (272)
- Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. (2008) (267)
- Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation (2011) (262)
- Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. (2012) (252)
- Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. (2009) (247)
- Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. (2012) (247)
- Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. (2006) (238)
- Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. (2010) (225)
- KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (2009) (209)
- Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission (2016) (189)
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (187)
- Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2004) (183)
- Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia (2015) (181)
- CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. (2013) (181)
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 (2019) (181)
- Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. (2001) (179)
- Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome (1998) (172)
- Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1997) (165)
- High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. (2006) (161)
- Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. (2002) (160)
- Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation (2012) (153)
- Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide (1991) (144)
- COVID-19 outcomes in patients with hematologic disease (2020) (144)
- A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia (1996) (142)
- Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. (2015) (135)
- Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. (2011) (135)
- Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. (2017) (133)
- Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). (1996) (130)
- Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (1996) (121)
- Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies (2007) (119)
- Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia (2011) (118)
- Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide (2018) (117)
- Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (2015) (115)
- Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. (2009) (114)
- Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia (2016) (113)
- Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT (2012) (111)
- Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT (2018) (110)
- Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? (2012) (109)
- Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation (2008) (108)
- Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. (2019) (107)
- Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation (2007) (105)
- Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and (2013) (105)
- The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). (1996) (104)
- Competing risks regression for clustered data. (2012) (104)
- Unrelated cord blood transplants in adults with hematologic malignancies. (2006) (104)
- Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (1997) (103)
- Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia (2000) (101)
- Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE) (2019) (99)
- Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant (2017) (98)
- A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study (2011) (97)
- Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. (2015) (97)
- KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (2009) (95)
- Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. (1998) (95)
- Transplantation of peripheral blood progenitor cells from HLA‐identical sibling donors (1996) (94)
- Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group (2005) (92)
- Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation (2007) (92)
- Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). (1996) (92)
- Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. (2015) (90)
- Prophylactic heparin does not prevent liver veno‐occlusive disease following autologous bone marrow transplantation (1991) (86)
- One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. (1994) (85)
- Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT (2014) (85)
- Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (85)
- Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire (2010) (82)
- Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (82)
- Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. (2012) (75)
- Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation. (2019) (75)
- Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse (2018) (75)
- A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia (2014) (72)
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2020) (72)
- A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia (2017) (71)
- Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (71)
- New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. (2013) (71)
- European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching (1997) (71)
- Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? (2016) (71)
- Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. (2010) (70)
- Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry (2013) (70)
- Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. (2008) (69)
- Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. (2017) (69)
- Reduced‐intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2015) (69)
- Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. (2002) (69)
- Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. (1995) (69)
- Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (2013) (68)
- Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (67)
- Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission (2014) (65)
- Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. (2017) (65)
- No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission (2000) (65)
- Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation (2011) (65)
- Unrelated Cord Blood Transplantation: Outcomes After Single-Unit Intrabone Injection Compared With Double-Unit Intravenous Injection in Patients With Hematological Malignancies (2013) (64)
- Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. (2016) (63)
- Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT (2018) (61)
- Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients (2015) (60)
- Is there a graft‐versus‐leukaemia effect in the absence of graft‐versus‐host disease in patients undergoing bone marrow transplantation for acute leukaemia? (2000) (59)
- Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT (2017) (59)
- Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation (2007) (59)
- Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. (2014) (59)
- Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis (2000) (58)
- Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study (2016) (58)
- HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia (2007) (57)
- Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution. (1998) (56)
- Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (2020) (56)
- Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT (2018) (55)
- Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome (2008) (55)
- Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT (2016) (55)
- Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2018) (54)
- Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT (2016) (54)
- Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. (2003) (53)
- Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome (2019) (53)
- Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party (2015) (52)
- Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis (1997) (52)
- Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years (1997) (52)
- Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. (2009) (51)
- Monitoring of cytomegalovirus infection and disease in bone marrow recipients by reverse transcription-PCR and comparison with PCR and blood and urine cultures (1996) (51)
- Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow (2003) (50)
- Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Mal (2015) (49)
- European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). (1994) (49)
- Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. (2018) (49)
- Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis (2012) (49)
- Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Grou (2006) (48)
- Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation (2015) (48)
- Long-term cryopreservation of human stem cells. (1992) (48)
- Flt 3 ligand, MGDF, Epo and G-CSF enhance ex vivo expansion of hematopoietic cell compartments in the presence of SCF, IL-3 and IL-6 (1998) (47)
- Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. (2010) (46)
- Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation (2018) (46)
- Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT (2019) (45)
- Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects (2015) (45)
- Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. (2017) (45)
- Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies (2015) (45)
- Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. (2016) (45)
- OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. (2019) (44)
- Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study (2019) (44)
- Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes (2016) (44)
- Dose-effect relationship for cataract induction after single-dose total body irradiation and bone marrow transplantation for acute leukemia. (2002) (43)
- Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. (2015) (43)
- Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. (2010) (43)
- Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT (2015) (42)
- Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years (2015) (42)
- Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia (2017) (42)
- Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. (2018) (42)
- Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. (2012) (42)
- Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties (2019) (41)
- Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT (2019) (41)
- Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT (2018) (41)
- Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution. (1999) (41)
- Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease (2019) (41)
- Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT (2020) (41)
- Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). (2005) (40)
- Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party (2019) (40)
- Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database (2016) (40)
- Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: a retrospective study. (1992) (40)
- Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen (2014) (40)
- Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2015) (39)
- Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT (2016) (39)
- Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France (2014) (39)
- Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party (2020) (38)
- Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide (2018) (38)
- Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study (2020) (37)
- Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine (2018) (37)
- The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. (2017) (37)
- Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML) (2015) (37)
- Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT (2019) (37)
- Increase of Suicide and Accidental Death After Hematopoietic Stem Cell Transplantation (2013) (37)
- Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors? (2010) (37)
- Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2017) (37)
- Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. The EBMT Group Working Party for Autologous Bone Marrow Transplantation. (1991) (37)
- Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft (1999) (36)
- Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. (2018) (36)
- Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission (2018) (36)
- Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients (2012) (35)
- Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? (2016) (35)
- Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). (1994) (35)
- European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation (2018) (35)
- Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT (2017) (35)
- Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. (2017) (34)
- Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT (2017) (33)
- Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study (2016) (33)
- Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT (2016) (33)
- Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. (2003) (33)
- Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells (2000) (33)
- Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (33)
- Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission (2017) (32)
- Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. (2020) (32)
- Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT (2016) (32)
- Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD. (2012) (32)
- Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT (2014) (32)
- Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (1998) (32)
- Long‐term outcome after a treosulfan‐based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (31)
- Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (2020) (31)
- Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. (2019) (31)
- Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center (2018) (31)
- Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party (2017) (31)
- The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2015) (31)
- Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group (2018) (31)
- Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors (2020) (30)
- Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? (2018) (30)
- Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. (2018) (30)
- Autologous Haematopoietic Stem Cell Transplantation for Crohn’s Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation (2018) (30)
- Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation (2018) (29)
- Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? (2000) (29)
- Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT (2017) (29)
- Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study (2019) (29)
- Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT (2019) (29)
- Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis (2018) (28)
- RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT (2016) (28)
- The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed (2000) (28)
- T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis (2015) (28)
- Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (28)
- Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia (2020) (28)
- Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT (2020) (28)
- Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen (2018) (27)
- Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial (2014) (27)
- Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. (2017) (27)
- Clofarabine‐containing conditioning regimen for allo‐SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT (2012) (27)
- Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis (2014) (27)
- Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years (2020) (26)
- Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. (2017) (26)
- Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (2019) (26)
- Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT (2019) (26)
- The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation (2018) (26)
- Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT (2017) (26)
- Reduced‐toxicity conditioning with fludarabine, once‐daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial (2015) (26)
- Thiotepa‐based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched‐pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (26)
- Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study (2016) (26)
- Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1997) (25)
- Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T‐cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2018) (25)
- Validation of the acute leukemia‐EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi‐center GITMO cohort (2017) (25)
- Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2015) (25)
- Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. (2018) (25)
- Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation (2021) (25)
- Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial (2015) (25)
- An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia (2017) (25)
- The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT (2013) (25)
- Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand? (2017) (25)
- Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT (2017) (25)
- Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation (2015) (25)
- Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant (2010) (24)
- Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT (2016) (24)
- Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation (2003) (24)
- Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia (2020) (24)
- Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation (2014) (24)
- Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years (2009) (23)
- Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study (2018) (23)
- Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (23)
- Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations (2021) (22)
- Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT (2019) (22)
- Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (22)
- Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia (2020) (22)
- Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia (2019) (22)
- Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). (2002) (22)
- Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (21)
- Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients (2019) (21)
- Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia (2020) (21)
- Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT (2016) (21)
- Mobilized peripheral blood stem cells compared with bone marrow from HLA‐identical siblings for reduced‐intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT (2012) (21)
- Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT (2019) (21)
- The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party (2016) (21)
- T‐cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3‐ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2018) (21)
- Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia : Better Outcomes with Busulfan and Melphalan Compared with Busulfan and Cyclophosphamide in High Risk Patients Autografted in First Complete Remission (2017) (20)
- Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission (2013) (20)
- Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT (2012) (20)
- Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT (2017) (20)
- Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia (2020) (20)
- OUTCOMES OF UCB TRANSPLANTATION ARE COMPARABLE IN FLT3+ AML: RESULTS OF CIBMTR, EUROCORD AND EBMT COLLABORATIVE ANALYSIS (2016) (20)
- Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. (2018) (20)
- Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. (1994) (19)
- More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party (2017) (19)
- Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting (2019) (19)
- Occurrence of graft‐versus‐host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT (2018) (19)
- Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT (2017) (18)
- Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia (2021) (18)
- Anti‐thymocyte globulin improves survival free from relapse and graft‐versus‐host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia‐negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT (2018) (18)
- Haematopoietic stem cell transplantation in children in eastern European countries 1985–2004: development, recent activity and role of the EBMT/ESH Outreach Programme (2008) (18)
- Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow T (2020) (18)
- Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation (2018) (18)
- Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia (2018) (18)
- Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis (2016) (18)
- Outcomes of Unrelated Cord Blood and Haploidentical Stem Cell Transplantation in Adults with Acute Leukaemia. (2005) (18)
- Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission (2017) (18)
- Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia (2018) (17)
- Individualized prediction of leukemia‐free survival after autologous stem cell transplantation in acute myeloid leukemia (2019) (17)
- Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT (2015) (17)
- Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin (2019) (17)
- Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome (2014) (17)
- Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2020) (17)
- Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party (2019) (17)
- Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). (1997) (17)
- Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT (2021) (17)
- Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT (2017) (17)
- Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study (2019) (16)
- Transplantation of allogeneic peripheral blood progenitor cells--the EBMT experience. (1996) (16)
- Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2014) (16)
- Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission (2008) (16)
- Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. (1997) (16)
- Comparison of CD34+ bone marrow cells purified by immunomagnetic and immunoadsorption cell separation techniques (1998) (16)
- Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over (2019) (15)
- Thiotepa‐based versus total body irradiation‐based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantati (2016) (15)
- Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis (2018) (15)
- Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? (2016) (15)
- Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis (2014) (15)
- Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study (2010) (15)
- Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. (2014) (15)
- Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. (2021) (14)
- Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study (2018) (14)
- Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia. (2014) (14)
- Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year‐old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT) (2015) (14)
- Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide. (1995) (14)
- Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC (2018) (14)
- ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT (2017) (14)
- Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission (2020) (14)
- Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors. (2015) (14)
- Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells (2019) (14)
- Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies (2019) (13)
- Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia (2018) (13)
- Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2019) (13)
- Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT (2017) (13)
- Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). (1991) (13)
- Relatively favorable outcome after allogeneic stem cell transplantation for BCR‐ABL1‐positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT) (2018) (13)
- 9 Clinical and endocopic improvement following hemopoietic stem cell transplantation in the ASTIC trial (2013) (13)
- Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (13)
- Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT (2009) (12)
- Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2018) (12)
- Comparative outcomes of myeloablative and reduced‐intensity conditioning allogeneic hematopoietic cell transplantation for therapy‐related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation (2019) (12)
- Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT (2016) (12)
- Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS (2016) (12)
- Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes (2019) (12)
- Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1999) (12)
- Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto‐SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM‐TC (2015) (11)
- Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission (2018) (11)
- Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia (2017) (11)
- Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT (2019) (11)
- Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia? (2014) (11)
- Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia (2021) (11)
- The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation (2019) (11)
- Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT (2021) (11)
- Thiotepa‐based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia—A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2017) (11)
- Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission (2020) (11)
- AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation (2018) (11)
- What is the outcome in patients with acute leukaemia who survive severe acute graft‐versus‐host disease? (2018) (11)
- Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. (2016) (11)
- Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. (2007) (10)
- Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party (2020) (10)
- Autologous bone marrow transplantation for childhood acute myeloid leukemia : a European survey (1991) (10)
- Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. (2019) (10)
- Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT). (2005) (10)
- In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? (2015) (10)
- Impact of detectable measurable residual disease on umbilical cord blood transplantation (2020) (10)
- Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status (2016) (10)
- Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (2017) (10)
- FLAMSA-based reduced intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an ALWP/EBMT analysis. (2020) (10)
- Efficacy, safety and long term results of prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia: a registry-based evaluation on 343 patients by the acute leukemia working party of EBMT. (2015) (10)
- Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. (2019) (10)
- Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT (2018) (10)
- Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis (2016) (9)
- Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT. (2019) (9)
- Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party (2020) (9)
- Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT (2021) (9)
- Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (2019) (9)
- Graft‐versus‐host disease and graft‐versus‐leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT (2019) (9)
- A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study (2021) (9)
- Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation—a retrospective study by the Acute Leukemia Working Party of EBMT (2020) (9)
- Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells (2004) (9)
- Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers (2013) (9)
- Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia : a European survey (1991) (9)
- Impact of total body irradiation‐ vs chemotherapy‐based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia (2020) (8)
- Association Between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). (2009) (8)
- Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT (2022) (8)
- A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality (2014) (8)
- Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2015) (8)
- Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. (2021) (8)
- T‐cell–depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT) (2018) (8)
- Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation (2021) (8)
- Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study (2019) (8)
- Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) (2019) (7)
- Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases (2008) (7)
- Fludarabine, IV Busulfan and Antithymocyte Globulins-Based Reduced-Toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation (allo-SCT): Results of a Multicenter Prospective Trial (2012) (7)
- The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. (2020) (7)
- Allogeneic Transplantation in Patients with HIV-Infection:A Pair Matched Cohort Study by the European Society forBlood and Marrow Transplantation (2015) (7)
- OP021 Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (2018) (7)
- Risk Factors for Outcome after Haploidentical Hematopoietic Stem Cell Transplant in Children with Very High Risk Acute Lymphoblastic Leukemia: Impact of Centre Experience. A Survey on Behalf of the ALWP and PDWP of the EBMT. (2006) (7)
- Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) (2008) (7)
- High‐dose post‐transplant cyclophosphamide impairs γδ T‐cell reconstitution after haploidentical haematopoietic stem cell transplantation using low‐dose antithymocyte globulin and peripheral blood stem cell graft (2020) (7)
- Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia (2021) (7)
- Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT (2016) (7)
- Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (7)
- Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC (2020) (7)
- Outcome of 5651 hematopoietic stem cell transplants for hematological malignancies carried out in Europe in 1993: a reliability study of the registry (2002) (7)
- Transfusion‐related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory (2018) (7)
- Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT (2019) (7)
- Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution. (2014) (7)
- Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (6)
- Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR (2015) (6)
- Unrelated Cord Blood Transplantation: Comparison After Single Unit Cord Blood Intrabone Injection and Double Unit Cord Blood Transplantation In Patients with Hematological Malignant Disorders. A Eurocord-EBMT Analysis (2010) (6)
- The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT) (2020) (6)
- A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant (2004) (6)
- The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood (2014) (6)
- Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT (2014) (6)
- Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia (2018) (6)
- Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation (2020) (6)
- Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the (2021) (6)
- Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT (2016) (6)
- Interpretable Boosted Decision Trees for Prediction of Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation (2016) (5)
- Post-Transplant Cyclophosphamide (PT-Cy) for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Transplantation from HLA Identical Sibling and Matched Unrelated Donor for Patients with Acute Leukemia, on Behalf of ALWP-EBMT (2017) (5)
- Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020) (5)
- Immune Response to the 23-Valent Polysaccharide Pneumococcal Vaccine (PPV23) after the 7-Valent Conjugate Vaccine (PCV7) in Allogeneic Stem Cell Transplant (SCT) Recipients: Results of the EBMT IDWP01 Trial (2008) (5)
- Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT) (2022) (5)
- Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. (2019) (5)
- Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia (2022) (5)
- Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission (2020) (5)
- Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia--a European survey. EBMT Working Party on ABMT. (1991) (5)
- Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia (2010) (5)
- Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. (2020) (5)
- Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC (2018) (5)
- Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. (2020) (5)
- Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia (2020) (5)
- Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation (2018) (5)
- Outcome of T‐cell–replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (5)
- The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA‐matched allogeneic stem cell transplantation (2019) (5)
- Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT (2022) (4)
- Hematopoietic cell transplant nurse coordinators’ perceptions of related donor care: a European survey from the EBMT Nurses Group (2019) (4)
- Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning (4)
- Prediction of allogeneic hematopoietic stem cell transplantation (allo-HSCT) related mortality in acute leukemia: generation of a machine learning-based model using the data set of the acute leukemia working party (ALWP) of the EBMT (2013) (4)
- Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT (2022) (4)
- Post remission consolidation by autologous HCT for AML in CR1, negative implications for subsequent allogeneic HCT in CR2. A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). (2019) (4)
- Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT (2021) (4)
- Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party (2018) (4)
- Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT (2015) (4)
- Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis. (2022) (4)
- 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. (2022) (4)
- Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party (2020) (4)
- Phenotypic Description of Familial Chronic Myeloproliferative Disorders. (2004) (4)
- Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT. (2022) (4)
- Metabolic syndrome is common following haematopoietic cell transplantation (HCT) and is associated with increased cardiovascular disease: an EBMT cross-sectional non-interventional study (2015) (4)
- Allogeneic Stem-Cell Transplantation for Patients with De Novo Acute Myeloid Leukemia Not in Complete Response: Results of a Survey from the European Group for Blood and Bone Marrow Transplantation (EBMT). (2004) (4)
- Corrigendum: Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry (2013) (4)
- Investigating covariate-by-centre interaction in survival data (2018) (4)
- Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation. (2020) (4)
- Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2012) (4)
- Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT (2010) (4)
- Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT (2014) (4)
- Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT (2013) (4)
- Outcomes After Double Cord Blood Transplantation Compared to Single Cord Blood Transplantation in Adults with Acute Leukemia Given a Reduced Intensity Conditioning Regimen (2012) (4)
- Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2021) (4)
- Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT (2008) (3)
- Impact of FAB classification on predicting outcome in acute myeloid leukemia , not otherwise specified , patients undergoing allogeneic stem cell transplantation in CR 1 (3)
- Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study (2021) (3)
- Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure (2014) (3)
- Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients (2014) (3)
- Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission (2021) (3)
- Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia – a study of the Acute Leukemia Working Party of the EBMT (2020) (3)
- The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT) (2016) (3)
- Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT (2020) (3)
- Growth factor‐associated graft‐versus‐host disease and mortality 10 years after allogeneic bone marrow transplantation (2012) (3)
- Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT (2020) (3)
- Comparison of Outcomes of Mismatched Related Stem Cell and Unrelated Cord Blood Transplants in Children with Severe T-Cell Deficiencies. (2009) (3)
- HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2015) (3)
- Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT (2019) (3)
- Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission (2019) (3)
- Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for > 55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT (2014) (3)
- The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML (2022) (3)
- Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukemia in patients over 60 years of age (2000) (3)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT. (2010) (3)
- Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT (2012) (3)
- Impact of the addition of antithymocyte globulin to post-transplant cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplant cyclophosphamide alone in acute myeloid leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT. (2022) (3)
- The Influence of Monosomal Karyotype On Survival in Patients with Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Survey On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2011) (3)
- Measurable residual disease, FLT3‐ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1‐mutated acute myeloid leukemia (2022) (3)
- Treatment of acute myeloid leukemia. (1999) (2)
- Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in First Complete Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party (2016) (2)
- Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT (2018) (2)
- Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2015) (2)
- Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT (2022) (2)
- The Intra-Bone Route of Administration of Cord blood cells extends the Possibility of Transplantation to the Majority of Patients with Malignant Hematopoietic Diseases. (2009) (2)
- Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia. (2004) (2)
- 828 Prolonged Regression of Ileocolonic Crohn's Disease Following Autologous Haemopoetic Stem Cell Transplantation: Presentation on Behalf of the Astic Trialists (2015) (2)
- RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT (2014) (2)
- Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year‐old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT) (2016) (2)
- Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Matched or Mismatched 9/10 Unrelated Donors in Acute Lymphoblastic Leukemia in First Complete Remission: On Behalf of the ALWP of the EBMT (2018) (2)
- Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT (2020) (2)
- Long-Term Follow-up of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML): A Survey of 3567 Patients From the Acute Leukemia Working Party of the EBMT. (2012) (2)
- Comparison of RIC-alloHCT and autoHCT for > 55 years old patients with acute lymphoblastic leukemia: an analysis from Acute Leukemia Working Party of the EBMT (2015) (2)
- Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT (2014) (2)
- Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study (2019) (2)
- HLA-haploidentical transplantation for relapsed/refractory AML: better LFS with BM than with PBSC in patients ≥ 55 years of age. (2022) (2)
- PF747 DEFIBROTIDE TREATMENT IN ADULTS WITH SEVERE OR VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE STUDY INTERIM RESULTS (2019) (2)
- Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems (2012) (2)
- Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT (2012) (2)
- Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease (GVHD): A Study on Behalf of the Acute Leukemia Working Party of EBMT. (2019) (2)
- Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party (2019) (2)
- Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT (2014) (2)
- Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT (2021) (2)
- Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia. (2004) (2)
- Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey. (2009) (2)
- Prediction of allogeneic HSCT related mortality in acute leukemia: exploring boundaries of prediction through machine learning based modeling. A data mining study from the acute leukemia working party (ALWP) of the EBMT (2014) (2)
- OC-004 Prediction of Clinical and Endoscopic Remission after Autologous Stem cell Transplantation in Treatment Refractory Crohn’s Disease: Pooled Results from the Astic Trial (2016) (2)
- Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT (2022) (2)
- Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (2020) (2)
- Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study (2017) (2)
- 93 Clinical and Endocopic Improvement Following Hemopoietic Stem Cell Transplantation vs Mobilisation Alone in Crohn's Disease (2013) (2)
- Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT (2018) (2)
- Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European society of Blood and Marrow Transplantation (EBMT) (2016) (1)
- Study of V617F JAK2-Positive and JAK2-Negative Patients within 18 Families with Myeloproliferative Disorders (MPD): Disease Characteristics and Evolution, EPOR and MPL Analysis. (2006) (1)
- Long-term persistence of the immune response toanti-pneumococcal vaccines after allogeneic stem celltransplantation: Ten years later after the EBMT-IDWP01trial (2015) (1)
- A haploidentical may be a better choice than a female genoidentical donor to transplant a patient with high risk acute myelogenous leukemia in first remission (2019) (1)
- Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study (2018) (1)
- Party disease: a retrospective study of the EBMT Autoimmune Disease Working Secondary autoimmune diseases occurring after HSCT for an autoimmune (2011) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT (2015) (1)
- Human leukocyte antigen‐haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia‐free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age (2022) (1)
- Myeloablative Chemo-Conditioning for First Hematopoietic STEM CELL Transplantation in Children with ACUTE Lymphoblastic Leukemia in First or Second Remission (2014) (1)
- PV-0042: Fractionated-TBI schedules prior to allograft: Study from the Acute Leukemia Working Party (EBMT) (2017) (1)
- Impact of Minimal Residual Disease at Unrelated Cord Blood Transplantation In Children with Acute Lymphoblastic Leukemia In Remission: a Study on Behalf of Eurocord-EBMT and EBMT-PDWP (2010) (1)
- Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study (2014) (1)
- Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT (2011) (1)
- Reduced intensity regimen using low dose total body irradiation prior to allogeneic transplant for hematologic malignancies: A retrospective review from the acute leukemia working party of the European Bone Marrow Transplant Group (2005) (1)
- Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell Transplantation (2014) (1)
- Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT (2021) (1)
- Outcomes after HLA-Identical Sibling Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced Intensity Conditioning Compared to Autologous Peripheral Blood Stem Cell Transplantation for Elderly Patients with De Novo Acute Myeloid Leukemia. (2005) (1)
- Machine learning based predictive modeling for mortality 100 days post allogeneic hematopoietic stem cell transplantation (ALLO-HSCT) in acute leukemia: an EBMT-acute leukemia working party (ALWP) registry study (2014) (1)
- unrelated cord blood? Transplantation in patients with SCID: mismatched related stem cells or (2014) (1)
- Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation (2020) (1)
- Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity (2015) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (1)
- Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2020) (1)
- Upfront Autologous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma (MM) Patients: A Prospective Multicenter Study (2015) (1)
- PTU-083 Substantial histological improvement following haemopoetic stem cell transplantation (2015) (1)
- Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3‐ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation (2022) (1)
- T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT (2013) (1)
- Larger Number of Invariant Natural Killer T-Cells in Allogeneic Peripheral Blood Stem Cell Grafts Is Associated with Improved Graft-Versus-Host Disease-Free, Progression-Free Survival after Allogeneic Stem Cell Transplantation (2015) (1)
- Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (2022) (1)
- Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT (2023) (1)
- Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT (2014) (1)
- Association Between The Hematopoietic Cell Transplantation-Specific Comorbidity Index (CIn) And Non-Relapse Mortality (NRM) After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (Allo-SCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1) (2010) (1)
- Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT (2013) (1)
- Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT (2015) (1)
- Comparison Of Unrelated Cord Blood (CB) and Peripheral Blood Stem Cell (PB) Transplantation In Adults With Myelodysplastic Syndrome (MDS) After Reduced Intensity Conditioning Regimen (RIC): A Collaborative Study From Eurocord and Chronic Malignancies Working Party (CMWP-EBMT) (2013) (1)
- Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission: An Analysis By the Acute Leukemia Working Party of the EBMT (2016) (1)
- Impact of dose intensity on unrelated cord blood transplantation outcomes in adults patients with acute leukemia: A Report from Eurocord, the ALWP and the Cord Blood Committee of the CTIWP of the EBMT (2016) (1)
- Non-T Depleted Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Secondary Versus De Novo AML: A Study from the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2023) (1)
- The Impact of Center Experience on Results of Reduced Intensity – Allogeneic Hematopoietic Stem Cell Transplantation. A Survey From the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT) (2010) (1)
- OC-014 Clinical and Endoscopic Improvement following Hemopoietic Stem Cell Transplantation vs Mobilisatiion alone in Crohn’S Disease (2013) (1)
- Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation (2020) (1)
- Safety and Efficacy of Donor T Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK Cells) Given after T-Cell Depleted (TCD) Haploidentical Hematopoietic Transplantation (Haplo-HSCT): Results of a 14-Year Follow-Up in 45 Patients (2017) (1)
- Mismatched Unrelated Donor Allo-SCT for AML after Reduced Intensity or Ablative Conditioning Regimen—A Report from the Acute Leukemia Working Party of the EBMT (2015) (1)
- The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT (2018) (1)
- Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey. (2007) (1)
- Different Approaches Of Allogeneic Stem Cell Transplantation For Acute Leukemias In Suzhou (China) Lead To Similar Outcome Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis (2013) (1)
- Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party (2019) (1)
- Is There a Stronger Graft-Versus-Leukemia Effect Using HLA-Haplo-Identical Donors Compared to HLA-Identical Sibling Donors? (2015) (1)
- Intravenous Busulfan (IV Bu)-Based Conditioning Regimen Before Allogeneic Stem Cell Transplantation (allo-SCT) for Adults with Acute Lymphoid Leukemia (ALL): A Aurvey From the Acute Leukemia Working Party of EBMT (2011) (1)
- Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid leukaemia in complete remission: a retrospective analysis from the ALWP of EBMT in BONE MARROW TRANSPLANTATION, vol 45, issue , pp S21-S22 (2010) (1)
- Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT (2020) (1)
- Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party (2022) (1)
- Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT (2022) (1)
- Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. (2022) (1)
- Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation (2017) (1)
- Factors Determining Survival after Unrelated Donor Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia (2008) (1)
- Heterogeneous Distribution of the JAK2 Val617Phe Activating Mutation in Familial Myeloproliferative Disorders. (2005) (1)
- Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. (2021) (1)
- Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia Working Party Registry (2015) (1)
- Busulfan (Bu) Plus Cyclophosphamide (Cy) Versus TBI Plus Cy Conditioning for Allogeneic Stem Cell Transplantation (alloSCT) From Matched Unrelated Donors (MUD) In Adult Patients with AML in First Relapse: A Survey From the Acute Leukemia Working Party of EBMT (2011) (1)
- Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT (2015) (1)
- Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT (2016) (1)
- Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT (2022) (1)
- Allogeneic Hematopoietic Stem-Cell Transplantation In Early Phase Might Overcome the Adverse Prognosis of Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34)/DEK-NP214(CAN) Rearrangement. A Retrospective Analysis From the Acute Leukemia Working Party of EBMT (2010) (1)
- Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation (2022) (1)
- A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT (2015) (1)
- Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (2022) (1)
- The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study (2020) (1)
- remission at transplantation in adults with high-risk acute leukemia : a risk factor analysis of A survey of fully haploidentical hematopoietic stem cell transplantation (2008) (1)
- Similar Outcome Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning in Children: A Retrospective Study from the SFGM-TC (2014) (1)
- FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT (2018) (1)
- Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study (2019) (1)
- Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT (2021) (1)
- Diagnosis of Lupus, age at HSCT and CD34+graft selection are the main risk factors for secondary autoimmune diseases occurring after HSCT for autoimmune diseases: a retrospective study of the EBMT Autoimmune Disease Working Party (2011) (1)
- Total-body irradiation before bone-marrow transplantation for acute leukemia in first or second complete remission (1994) (1)
- Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT (2021) (1)
- Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia (AML) with 11q23 (MLL) Rearrangement (MLL-r AML). A Retrospective Analysis From the Acute Leukemia Working Party of EBMT (2011) (1)
- Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (1)
- GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT (2023) (1)
- Results of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the FAB M0 Subtype in First Complete Remission: A Survey of the Acute Leukemia Working Party of the European Bone Marrow Transplant Group (EBMT). (2004) (1)
- Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study (2017) (1)
- Impact of ABO-Mismatching Following HLA- Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for AML—a Report From the ALWP of the EBMT (2017) (1)
- Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation (2022) (0)
- Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT (2011) (0)
- Syngeneic Hematopoietic Stem Cell Transplantation in Acute Leukaemia. A Report of the Acute Leukaemia Working Party of the EBMT. (2004) (0)
- Autologous Hematopoietic Stem Cell Transplantation In Neuromyelitis Optica: A Retrospective Study Of The EBMT Autoimmune Diseases Working Party In Collaboration With The University Of Sao Paulo, Ribeirao Preto, Brazil (2013) (0)
- Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis (2022) (0)
- Long-Term Follow-up of 94 Families with Myeloproliferative Neoplasms: Implications of the V617F JAK2 mutation, Life Expectancy and Complication Rates (2010) (0)
- Defining the Prognostic Implications of Recurring Cytogenetic Aberrations and FLT3-ITD in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation: On Behalf of the ALWP of the EBMT (2019) (0)
- Outcome of Two Loci Mismatched (≤6/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study (2019) (0)
- Who Is the Best Haematopoietic Stem Cell Donor for a Male Patient with Acute Leukaemia (2014) (0)
- Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT (2020) (0)
- Standard Versus Single Dose-Daily Fractionated Total Body Irradiation Schedules Prior to Allotransplant for Acute Leukemia: The Sarasin Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2017) (0)
- Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT (2020) (0)
- Second A llogeneic B one M arrow T ransplantation i n A cute Leukemia: R esults o f a S urvey b y t he E uropean Cooperative G roup f or B lood a nd M arrow T ransplantation (2001) (0)
- Unrelated cord blood (ECB) transplantation for AML: higher incidence of acute GVHD and lower survival in male patients transplanted with female unrelated cord blood. A report from Eurocord and the ALWP of the EBMT (2015) (0)
- Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT (2022) (0)
- Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2023) (0)
- The Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation (2011) (0)
- Unmanipulated Graft Haploindentical Allogeneic Stem Cell Transplantation (Haplo-SCT) In Acute Leukemia: A Long-Term Follow-Up Survey On Behalf Of The Acute Leukemia Working Party (ALWP) Of The European Group For Blood and Marrow Transplantation (EBMT) (2013) (0)
- Refined graft-versus-host disease-free/relapse-free survival - a novel outcome endpoint for haploidentical transplantation in adults with acute leukemia: on behalf of ALWP-EBMT (2016) (0)
- Extracorporeal Photopheresis (ECP) for Acute Graft-Versus Host Disease (GvHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) (2015) (0)
- Chemotherapy Dose Adjustment For Obese Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Survey On Behalf Of The ALWP Of The EBMT (2013) (0)
- Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group (2017) (0)
- MRD Status Impact on Secondary Acute Myeloid Leukemia Outcomes after Allogeneic Hematopoietic Cell Transplantation. A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2021) (0)
- A prospective observational study on the feasibility of donor search and haematopoietic cell transplantation for adults with acute leukaemia (2010) (0)
- “Human Development Index” Correlates with Rates and Influences Outcome of Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia. (2009) (0)
- Poor Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for De Novo AML with Chromosome 7 Abnormalities: A Report for the ALWP of the European Group for Blood and Marrow Transplantation. (2007) (0)
- Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP) (2021) (0)
- Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT (2023) (0)
- Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (0)
- Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpla (2023) (0)
- Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT (2018) (0)
- Low Dose Total Body Irradiation Prior to Allograft for Heamtologic Malignancies: a Retrospective Review from the Acute Leukemia Working Party of the European Blood and Marrow Transplantation (2005) (0)
- Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT (2015) (0)
- Impact of Postremission Consolidation Chemotherapy On Outcome After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for AML in First Complete Remission (CR1): A Report From the Acute Leukemia Working Party of EBMT. (2012) (0)
- Impact of alemtuzumab versus anti-thymocyte globulin after unrelated allogeneic stem cell transplantation with reduced-intensity conditioning as treatment for AML in CR1: a survey from the Acute Leukaemia Working Party of the EBMT (2012) (0)
- Bone Marrow or Peripheral Blood Stem Cell Transplantation From Unrelated Donors in Adult Patients With Acute Myeloid Leukemia (2011) (0)
- Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission. (2023) (0)
- Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2023) (0)
- Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Cord Blood Transplantation (CBT). Retrospective Analysis on Behalf of Eurocord and the EBMT Autoimmune Diseases Working Party. (2010) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2019) (0)
- Autologous Versus Haploidentical Stem Cell Transplantation in Adult Patients with Intermediate Risk Actue Myelogenous Leukemia in First Complete Remission and Undetectable Minimal Residual Disease: A Global Preliminary Analysis of Chinese Data (2022) (0)
- Evaluation of Trends in Outcome over 2 Decades of Patients with Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplantation from Unrelated Donors: An ALWP/EBMT Analysis (2022) (0)
- Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study? (2014) (0)
- A prospective study on the feasibility of related and unrelated donor search and haematopoietic cell transplantation for adults with acute leukaemia at 31 European transplant centres (2008) (0)
- How to study therapy dilemmas with respect to BMT (1993) (0)
- Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial (2016) (0)
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2021) (0)
- Association Of Health Care Expenditure With Results Of Allogeneic HSCT For Adults With ALL: An Analysis From Acute Leukemia Working Party Of The EBMT (2013) (0)
- Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study (2010) (0)
- S114 POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT (2019) (0)
- Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2015) (0)
- Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party (2012) (0)
- Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission (2012) (0)
- A Scoring System Predicting Outcome After Unrelated Donor Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia (2011) (0)
- Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated AML patients: on behalf of the ALWP/EBMT (2022) (0)
- 80 Cataracts following bone marrow transplantation (BMT) conditioned with total body irradiation (TBI) for acute leukemia (AL) in complete remission (CR): A study of the European group for blood and marrow transplantation (1997) (0)
- Cataract induction after total body irradiation and bone marrow transplantation: Dose-effect relationship (2000) (0)
- Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT (2013) (0)
- The Optimal Alternative Donor Transplant for Pediatric Patients with Acute Leukemia: A Comparison between Alfa-Beta T-Cell and B-Cell Depleted Haplo-SCT and UCBT (2018) (0)
- Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT 3-ITD ; a study from the Acute Leukemia Working (2017) (0)
- Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1) (2021) (0)
- Outcome of Patients with Primary Refractory Acute Myeloid Leukemia (AML) Undergoing Myeloablative Allogeneic Stem-Cell Transplantation (alloSCT) from HLA-Identical Sibling: Favorable Outcome in a Subset of Patients. (2006) (0)
- Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients (Pts) with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Pooled Analysis of Defifrance and EBMT PASS Registries (2023) (0)
- The hierarchy of alternative donors for allogeneic hematopoietic stem cell transplantation in poor risk Aml in CR1 revisited (2016) (0)
- Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation Transplantation and Cellular Therapy (2022) (0)
- Impact of Pre-Emptive Rituximab Treatment for Epstein-Barr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Longitudinal Study of 110 Patients (2017) (0)
- Allogeneic versus autologous bone marrow transplantation in adults with AML in first complete remission: A new approach for a fair retrospective comparison. (1998) (0)
- Impact of CD34+ Cell Dose on Clinical Outcomes after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from Haploidentical Donors in AML Patients. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (0)
- Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning for adults with Ph(-) all undergoing Allo-Hct. A study from the Acute Leukemia Working Party of the EBMT. (2017) (0)
- Risk Factors of Outcomes after Haploidentical Hematopoietic Stem Cell Transplants for Children with High Risk Acute Leukaemia. A Survey on Behalf of the EBMT. (2005) (0)
- Allogeneic Transplant for Mixed Phenotype Acute Leukemia (MPAL): Characteristics and Outcome in the ALWP-EBMT Database (2017) (0)
- Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT (2014) (0)
- Haploidentical Mismatched Allogeneic Versus Autologous Hematopoietic STEM CELL Transplantation in Adult Patients with ACUTE Myeloid Leukemia (AML) in First Complete Remission (CR1): A Pair-Matched Analysis From the Acute Leukemia Working Party of EBMT. (2012) (0)
- Sequential Chemotherapy Followed by Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of EBMT (2012) (0)
- Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT (2019) (0)
- Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML) (2013) (0)
- families with myeloproliferative disorders Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 (2013) (0)
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT, (2011) (0)
- A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT) (2019) (0)
- Comparison of Matched Sibling, Unrelated and Haploidentical Donor Transplants Using Post-Transplant Cyclophosphamide in Patients with Acute Myeloid Leukemia, a Study of the ALWP EBMT (2020) (0)
- Risk Factors for Outcomes of Family Haploidentical Allogeneic Stem Cell Transplantation for Adults with Acute Leukemias: A Survey on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (2004) (0)
- Exploring limiting factors in the prediction of allogeneic HSCT related mortality: an in-silico machine learning analysis of the acute leukemia working party (ALWP) registry of the EBMT (2015) (0)
- Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission (2015) (0)
- 2 amongst patients undergoing autologous transplant for multiple myeloma : a multicentre UK study (2017) (0)
- Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. (2023) (0)
- Impact of Conditioning Regimen on Outcomes of T-Replete Haplo-Identical Transplantation for Patients Over 45 Years-Old with AML: A Study On Behalf Of the Acute Leukemia Working Party of the EBMT (2017) (0)
- CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2022) (0)
- Comparison of Outcome after Allogeneic Stem Cell Transplantation in AML Patients in First or Second Complete Remission Following Either Fludarabin/Busulfan, Flamsa-TBI or Flamsa-Bu Conditioning (2017) (0)
- Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT (2013) (0)
- P1371: GRAFT-VERSUS-HOST DISEASE OFFERS NO GRAFT-VERSUS-LEUKEMIA ADVANTAGE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLO-IDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (2022) (0)
- Prognostic factors for clinical response treated by allogeneic mesenchymal stem cell in adult patients with systemic lupus erythematosus (2018) (0)
- Unrelated Allogeneic Stem Cell Transplantation with Myeloablative Conditioning in Adults with Acute Lymphoblastic Leukemia in Remission: Peripheral Blood or Bone Marrow?. (2007) (0)
- Short title: Outcome of related and unrelated HSCT for SCID (2017) (0)
- PTU-082 Responders to haemopoietic stem cell transplantation for crohn’s disease (2015) (0)
- The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment : A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2015) (0)
- Second Allogeneic Stem Cell Transplantation (allo-SCT) Using Reduced-Intensity Conditioning (RIC) for Acute Myeloid Leukemia (AML) Patients Who Relapsed Following a First RIC Allo-SCT: a Survey From the Acute Leukemia Working Party of EBMT. (2010) (0)
- Factors determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a survey from the Acute Leukaemia Working Party of the EBMT (2015) (0)
- THIOTEPA-BASED CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOID LEUKEMIA (AML) - A SURVEY FROM THE ALWP OF THE EBMT (2014) (0)
- Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis (2022) (0)
- TRANSPLANTATION Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation Group of Bone Transplantation (2015) (0)
- Outcome after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality (2008) (0)
- Calcineurin Inhibitor Alone or in Combination with Mycophenolate Mofetil for Graft-Versus-Host-Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Transplantation from Matched Unrelated Donors: A Study from the ALWP of the EBMT (2020) (0)
- Comorbidities in recipients of low transplant conditioning intensity regimens for acute myeloid leukemia: an ALWP EBMT study. (2023) (0)
- Autogous bone marrow transplantation for childhood acute myeloid leukemia--a European survey. EBMT Working Party on ABMT. (1991) (0)
- Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT. (2009) (0)
- Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience (2015) (0)
- Autologous Stem Cell Transplantation For Acute Leukemias In Suzhou (China): Similar Outcome In CR1 Patients Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis (2013) (0)
- Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. (2023) (0)
- European Group for Blood and Marrow Transplantation registry Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus : data from the (2012) (0)
- Physicians Abstracts (2015) (0)
- Higher Incidence of Relapse with Peripheral Blood Rather Than Marrow as a Source of Stem Cells in Adults with Acute Myelocytic Leukemia, but Not in Adults with Acute Lymphocytic Leukemia Autografted during the First Remission (2008) (0)
- Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT (2020) (0)
- HLA disparities on unshared haplotype influence outcomes of unmanipulated haploidentical hematopoietic stem cell transplantation (HaploSCT): A Study from the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation (EBMT) (2016) (0)
- Unmanipulated Graft Transplantation From Family Haploidentical Donors: A Survey On 183 Adult Patients with Acute Leukemias On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2012) (0)
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Following Total Body Irradiation- the Effect of Anti- Thymocyte Globulin on Transplant Outcome: ALWP of the EBMT Study (2019) (0)
- Haploidentical Versus Autologous Stem Cell Transplantation in Adult Acute Leukemia: A Matched Pair Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2014) (0)
- The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007) (2022) (0)
- Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Pooled Analysis of Defifrance and EBMT PASS Registries (2022) (0)
- Autografting for acute myelocytic leukemia (AML) in Europe (2001) (0)
- Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients – A Report From The Acute Leukemia Working Party Of EBMT (2013) (0)
- Impact of Donor Type in Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Conditioning: A Study From the Alwp of the Ebmt and Eurocord (2018) (0)
- Variation in statistical reports and analysis on one and the same medical question. The Leukemia Working Partly. (1991) (0)
- Outcome of Children Developing Grade III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (2019) (0)
- Reply to F. Ferrara et al (2010) (0)
- Reduced-Intensity (FB2) Vs Reduced-Toxicity Myeloablative (FB3/FB4) Fludarabine/Busulfan Based Conditioning Regimens for Non-Hodgkin Lymphoma (NHL) Allografted Adult Patients: A Retrospective Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) (2016) (0)
- Higher Incidence of Relapse with Higher Doses of CD34+ Cells From Leukapheresis Products Infused in Adults with Acute Myelocytic Leukemia Autografted During the First Remission. (2009) (0)
- Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT (2019) (0)
- Defibrotide (DF) Treatment in Pediatric (ped) and Adult Patients (pts) with Severe or Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Final Results from the Defifrance Study (2022) (0)
- Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT (2022) (0)
- Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT (2016) (0)
- Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy. (2012) (0)
- Risk factors for CMV retinitis after allogeneic blood stem cell transplantation (2002) (0)
- DEFIBROTIDE TREATMENT IN PAEDIATRIC PATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE INTERIM RESULTS (2020) (0)
- Working Parties (1991) (0)
- Haploidentical Transplantation Outcomes for Secondary Acute Myeloid Leukemia—on Behalf of the ALWP of the EBMT (2018) (0)
- Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC (2022) (0)
- Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide (DF) for the Treatment of Severe/Very Severe Veno-Occlusive Disease/ Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT) (2022) (0)
- Haploidentical stem cell transplantation abrogates the prognostic impact of FLT3-ITD in acute myeloid leukemia. A report from the Acute Leukemia Working Party of the EBMT (0)
- Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Trans (2022) (0)
- Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation (2022) (0)
- REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS (2017) (0)
- Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia (2020) (0)
- ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS (CN-AML): OUTCOME, RISK FACTORS AND ROLE OF MOLECULAR SUBGROUPS IN 1006 PATIENTS - A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT (2014) (0)
- Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party (2022) (0)
- CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC (2015) (0)
- Stem Cell Source (2002) (0)
- Results of Non Myeloablative Geno-Identical Transplants in Adults with AML: Influence of the Doses of Peripheral Stem Cells Infused (on Behalf of the Acute Leukemia Working Party of EBMT). (2005) (0)
- Umbilical Cord Blood Transplantation for Secondary AML: A Retrospective Study From the Acute Leukemia Working Party of the Ebmt and Eurocord (2018) (0)
- Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI (2022) (0)
- Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2022) (0)
- Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT (2018) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML with Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center (2017) (0)
- Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide for the Treatment of Severe/Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation (2021) (0)
- Winning Cord Blood Unit Characteristics Impacting on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: a Collaborative Study of Eurocord and the Acute Leukemia Working Party of EBMT (2016) (0)
- MDS Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following Autologous Bone Marrow Transplantation for Patients With (2013) (0)
- Outcomes After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) In 163 Pediatric Patients (<18 years old): A Retrospective Study On Behalf Of The SFGM-TC (2013) (0)
- Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT (2022) (0)
- Outcomes of Defibrotide-Treated Patients (Pts) with Anicteric/Icteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Results from the Defifrance Registry Study (2022) (0)
- Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT (2022) (0)
- Outcome of Relapse After Allogeneic Transplantation for Childhood Acute Lymphoblastic Leukemia In Complete Remission. A Study of the Pediatric Diseases and Acute Leukemia Working Parties of the EBMT Group (2010) (0)
- Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT) (2015) (0)
- Comparison of Transplant Outcomes in Patients with Acute Lymphoblastic Leukemia after Haploidentical Transplant with Post-Transplant Cyclophosphamide or Matched Unrelated Donor Transplant (2020) (0)
- Acute myeloid leukemia with FLT 3 mutation : a therapeutic window for targeted therapy after allogeneic hematopoietic cell transplantation ( alloHCT ) (2017) (0)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT (2020) (0)
- KIR-Ligand Incompatibility in the Graft-Versus-Host Direction Is Associated with Better Outcomes after Unrelated Cord Blood Stem Cell Transplantation for Acute Leukemia in Complete Remission (2008) (0)
- Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT (2019) (0)
- Posttransplant cyclophosphamide‐based anti–graft‐vs‐host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen‐mismatched unrelated donors versus haploidentical donors: A study o (2022) (0)
- Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP) (2018) (0)
- Comparable survival for poor-risk cytogenetics AML in first complete remission after haploidentical donor or unrelated donor transplantation: a study from the ALWP of EBMT (2016) (0)
- Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Poor Karnofsky Performance Status Score. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (0)
- Outcomes of Acute Myelogenous Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide: Impact of Total Body Irradiation Versus Chemotherapy-Based Myeloablative Conditioning (2020) (0)
- Outcome of hematopoietic stem cell transplants in an observational versus a solicited data base. quality control study of the ebmt (2000) (0)
- Cost-Effectiveness of Double-Unit Cord Blood Transplantation Versus Single-Unit Cord Blood Transplantation in Adult Patients with Acute Leukaemia in France- On Behalf of SFGM-TC, Eurocord, ALWP-EBMT (2011) (0)
- Role of the graft-versus-leukaemia effect after reduced-intensity conditioning allogeneic stem cell transplantation as treatment for acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of the EBMT (2010) (0)
- Allogeneic Stem Cell Transplantation from Two Loci Mismatched (≤6/8) Unrelated Donors in Acute Leukemia: On Behalf of the ALWP of the EBMT (2020) (0)
- analysis of the European Bone Marrow Transplant Group retrospective myeloblastic leukemia in patients older than 50 years: a Autologous bone marrow transplantation for first remission acute (2011) (0)
- Allogeneic Stem Cell Transplantation from Haploidentical Versus Matched Sibling Donors for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2022) (0)
- Genoidentical PBSCT with reduced intensity conditioning compared to autologous PBSCT for old patients with acute leukemia: An EBMT matched pair analysis. (2002) (0)
- Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT (2021) (0)
- S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD (2019) (0)
- Non T–Cell Depleted Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2021) (0)
- Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT (2016) (0)
- Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT (2012) (0)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia (CMML): Prognostic Factors for Survival. A Report From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC), (2011) (0)
- Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT (2021) (0)
- Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation (0)
- Long Term Psycho-Social Aspects and Risk Factors for Severe Infections, Ocular, Pulmonary, Bone, Thyroid and Other Complications after Allogeneic Hematopoietic Stem Cell Transplantation for Children with Hematologic Malignancies. (2006) (0)
- 133 UNRELATED CORD BLOOD OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS RECEIVING A REDUCED INTENSITY CONDITIONING REGIMEN: AN EBMT STUDY (2015) (0)
- The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. (2019) (0)
- Comparison of haplo-identical versus unrelated allogeneic stem cell transplantation for acute myeloid leukemia with active disease: A report of 1578 patients from Acute Leukemia Working Party of EBMT (2016) (0)
- Acute myeloid leukemia Prognostic signi fi cance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia (2019) (0)
- Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. (2022) (0)
- Persistent Centre Effect but Improvement of Leukemia-Free Survival of HLA Identical Hematopoietic Stem Cell Transplantation for Adults with AML in First CR in Europe over the Period 1987–2005 an Analysis on Behalf of the ALWP of EBMT. (2006) (0)
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT (2022) (0)
- ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT (2017) (0)
- Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies (2021) (0)
- Clinical and endoscopic improvement following haemopoietic stem cell transplantation on behalf of the Autoimmune Diseases Working Party of the EBMT (2013) (0)
- Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study (2021) (0)
- The Role of Cytogenetic Risk Stratification in FLT3 Mutated NPM1 Negative AML Patients Undergoing Allogeneic Stem Cell Transplantation (alloSCT) in Remission: A Study on Behalf of the ALWP of the EBMT (2021) (0)
- The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT (2018) (0)
- Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study (2014) (0)
- Prediction of Leukemia-Free Survival Following Haploidentical Stem Cell Transplantation in Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT (2018) (0)
- Outcomes of adults with active or progressive hematological malignancies at time of allogeneic stem cell transplantation : a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2014) (0)
- Impact of chronic graft-versus-host disease (GVHD) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as treatment for acute myeloid leukemia (AML) : a survey from the Acute Leukemia Working Party of the EBMT (2011) (0)
- An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party (2016) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Poor Karnofsky Performance Status. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) (2020) (0)
- Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party (2022) (0)
- Allogeneic Stem Cell Transplantation for AML Patients with RUNX1 Mutation in First Complete Remission: A Study on Behalf of the ALWP of the EBMT (2020) (0)
- Donor Cell Derived Leukemia: Description Of 38 Cases and a Case Control Study (2013) (0)
- Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT (2018) (0)
- Donor Lymphocyte Infusion Vs. Second Allogeneic HCT In Relapsed AML After Allografting: A Landmark Analysis From The Acute Leukemia Working Party Of EBMT (2013) (0)
- Non-T-Cell Depleted Haploidentical Stem Cell Transplantation (haploHCT) with Post Transplantation Cyclophosphamide (PTCy)- the Role of Donor Kinship: From the ALWP of the EBMT (2021) (0)
- CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission (2022) (0)
- Determining Late Engraftment Following Single Cord, Unrelated Transplantation: An Analysis of the Eurocord Registry (2011) (0)
- Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE) (2023) (0)
- Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party (2012) (0)
- Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study (2022) (0)
- Impact of chronic graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (2012) (0)
- Autologous Bone Marrow Transplantation in Acute Myelocytic Leukemia in Europe: The Role of Marrow Purging (1994) (0)
- Allogeneic Stem Cell Transplantation for t(3;3)(q21;q26)/inv(3)(q21;q26) Acute Myeloid Leukemia - Report from the Acute Leukemia Working Party of the EBMT (2016) (0)
- Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (2022) (0)
- Title: Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia (2018) (0)
- Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT (2022) (0)
- Unrelated Allogeneic Stem Cell Transplantation with Myeloablative Preparative Regimen for Adult Patients with Acute Lymphoblastic Leukemia in CR: A Survey from the European Group for Blood and Marrow Transplantation (EBMT). (2006) (0)
- Effect of volume reduction of cord blood units before storage on transplantation outcomes: a retrospective analysis of Eurocord-EBMT and Netcord (2013) (0)
- Stem Cell TransplantationDecision Making and Problem Solving (2006) (0)
- Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation (2022) (0)
- Influence of Stem Cell Source (Bone Marrow versus Peripheral Blood) on Outcome after Reduced-Intensity Conditioning Regimens for Acute Leukemia—a Report from the Acute Leukemia Working Party of the EBMT (2015) (0)
- Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt) (2018) (0)
- International Registries Sites/Indications/Activity for Hsct in Autoimmune Diseases (2021) (0)
- What Is the Outcome of Patients with Acute Leukemia Who Survive Severe Acute Graft-Versus-Host Disease? (2017) (0)
- Haploidentical Stem Cell Transplantation Attenuates the Prognostic Impact of FLT3-ITD in Acute Myeloid Leukemia (2017) (0)
- Impact of Donor Type in Patients with Acute Myeloid Leukemia Given Allogeneic Hematopoietic Cell Transplantation after Low-Dose TBI Based Regimen: A Study from the Acute Leukemia Working Party of the EBMT and Eurocord (2017) (0)
- Impact of FLT3 Internal Tandem Duplication (FLT3/ITD) on the Outcome of HLA-Identical Sibling Hematopoietic Transplantation for Adult Acute Myeloid Leukemia (AML) in First Remission: Substantial Probability of Leukemia-Free Survival Despite Increased Relapse Risk. A Retrospective Analysis of the EBM (2007) (0)
- Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation (2022) (0)
- Disease Working Party autoimmune disease: a retrospective study of the EBMT Autoimmune Secondary autoimmune diseases occurring after HSCT for an (2012) (0)
- Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial (2022) (0)
- P1355: VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES OF DEFIBROTIDE-TREATED ADULT PATIENTS FROM THE DEFIFRANCE STUDY (2022) (0)
- Outcome of Patients with Second Cancer after Hematopoietic Stem Cell Transplantation: On Behalf of the Complications and Quality of Life Working Party of the EBMT (2016) (0)
- Direct Intra-Bone Cord-Blood Transplantation Overcomes the Problem of Graft Failure Even When Low Numbers of HLA-Mismatched Cord- Blood Cells Are Transplanted, Thus Leading to the Possibility of Use of This Technique in a Large Number of Patients. (2008) (0)
- Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis (2023) (0)
- Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia (2022) (0)
- (EBMT) study of the European Group for Blood and Marrow Transplantation Hematopoietic stem cell transplantation for de novo erythroleukemia: a (2013) (0)
- Autologous Vs Related Vs Unrelated Hematopoietic Stem Cell Transplantation for Adults with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the EBMT (2017) (0)
- Haematopoietic stem cell transplantation for sickle cell disease: an international survey on behalf of eurocord-monacord, EBMT paediatric disease working party and CIBMTR (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Myriam Labopin?
Myriam Labopin is affiliated with the following schools:
